Sequencing a tumor at the DNA level turns a single tissue sample into a map of the mutations that drive disease. The 12-gene plus microsatellite instability (MSI) panel applies amplicon-based next-generation sequencing to surface the alterations that determine whether targeted drugs will work. This focused design gives oncology teams a fast, economical genomic snapshot without the cost of a very large panel.
The assay enriches and sequences twelve cancer-related genes—including EGFR, KRAS, BRAF, ALK, and MET—directly from formalin-fixed, paraffin-embedded (FFPE) tissue. Library preparation uses multiplex polymerase chain reaction to amplify target regions, which keeps the workflow efficient even when starting material is limited. After sequencing, bioinformatics pipelines align reads, call single-nucleotide variants and small insertions or deletions, and compute MSI status by comparing the length distribution of repetitive loci against a stable reference. A report then lists each detected variant with its genomic position, allelic frequency, and a clinical-relevance annotation drawn from public variant databases.
Physicians order this panel for patients with advanced non-small cell lung cancer who need a focused genomic picture before committing to therapy. It suits cases where a broad panel is unnecessary but confirmation of the most actionable drivers is required. The MSI component adds value for patients being considered for immunotherapy, because high MSI predicts response to checkpoint inhibitors across tumor types.
One FFPE block or 5–10 unstained slides provides enough input for the test. Turnaround is typically 7–10 working days from sample receipt, and results are delivered as a structured PDF with variant tables and an interpretation summary. Re-extraction is available when initial nucleic acid quantity falls below the validated threshold.
Tissue scrolls should be shipped at ambient temperature with desiccant, while extracted nucleic acid travels on dry ice to preserve integrity. For hospital and distributor partners, batched submissions reduce per-sample cost and smooth laboratory scheduling. Give Life Time International supports repeat ordering and consolidated logistics for groups running the panel at volume.
Q: Which genes are included in the 12-gene panel? The panel covers EGFR, KRAS, BRAF, ALK, MET, and other high-frequency lung cancer drivers selected for their established link to approved therapies.
Q: How is MSI status determined from the same assay? The pipeline measures slippage at repetitive loci and compares the observed length distribution to a stable reference, classifying the sample as MSS, MSI-L, or MSI-H.
Q: What sample amount is needed when tissue is scarce? Five to ten unstained FFPE slides are usually sufficient, and the PCR-based library step tolerates lower input than whole-exome methods.
Q: Can the report guide first-line targeted therapy selection? Yes. Detected sensitizing variants such as EGFR exon 19 deletions or ALK fusions are reported with therapy associations to support first-line decisions.
Sequencing a tumor at the DNA level turns a single tissue sample into a map of the mutations that drive disease. The 12-gene plus microsatellite instability (MSI) panel applies amplicon-based next-generation sequencing to surface the alterations that determine whether targeted drugs will work. This focused design gives oncology teams a fast, economical genomic snapshot without the cost of a very large panel.
The assay enriches and sequences twelve cancer-related genes—including EGFR, KRAS, BRAF, ALK, and MET—directly from formalin-fixed, paraffin-embedded (FFPE) tissue. Library preparation uses multiplex polymerase chain reaction to amplify target regions, which keeps the workflow efficient even when starting material is limited. After sequencing, bioinformatics pipelines align reads, call single-nucleotide variants and small insertions or deletions, and compute MSI status by comparing the length distribution of repetitive loci against a stable reference. A report then lists each detected variant with its genomic position, allelic frequency, and a clinical-relevance annotation drawn from public variant databases.
Physicians order this panel for patients with advanced non-small cell lung cancer who need a focused genomic picture before committing to therapy. It suits cases where a broad panel is unnecessary but confirmation of the most actionable drivers is required. The MSI component adds value for patients being considered for immunotherapy, because high MSI predicts response to checkpoint inhibitors across tumor types.
One FFPE block or 5–10 unstained slides provides enough input for the test. Turnaround is typically 7–10 working days from sample receipt, and results are delivered as a structured PDF with variant tables and an interpretation summary. Re-extraction is available when initial nucleic acid quantity falls below the validated threshold.
Tissue scrolls should be shipped at ambient temperature with desiccant, while extracted nucleic acid travels on dry ice to preserve integrity. For hospital and distributor partners, batched submissions reduce per-sample cost and smooth laboratory scheduling. Give Life Time International supports repeat ordering and consolidated logistics for groups running the panel at volume.
Q: Which genes are included in the 12-gene panel? The panel covers EGFR, KRAS, BRAF, ALK, MET, and other high-frequency lung cancer drivers selected for their established link to approved therapies.
Q: How is MSI status determined from the same assay? The pipeline measures slippage at repetitive loci and compares the observed length distribution to a stable reference, classifying the sample as MSS, MSI-L, or MSI-H.
Q: What sample amount is needed when tissue is scarce? Five to ten unstained FFPE slides are usually sufficient, and the PCR-based library step tolerates lower input than whole-exome methods.
Q: Can the report guide first-line targeted therapy selection? Yes. Detected sensitizing variants such as EGFR exon 19 deletions or ALK fusions are reported with therapy associations to support first-line decisions.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
